BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 34330303)

  • 41. Clinical and functional implication of the components of somatostatin system in gastroenteropancreatic neuroendocrine tumors.
    Herrera-Martínez AD; Gahete MD; Pedraza-Arevalo S; Sánchez-Sánchez R; Ortega-Salas R; Serrano-Blanch R; Luque RM; Gálvez-Moreno MA; Castaño JP
    Endocrine; 2018 Feb; 59(2):426-437. PubMed ID: 29196939
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical, pathological and prognostic characteristics of gastroenteropancreatic neuroendocrine neoplasms in China: a retrospective study.
    Zhang X; Ma L; Bao H; Zhang J; Wang Z; Gong P
    BMC Endocr Disord; 2014 Jul; 14():54. PubMed ID: 25001493
    [TBL] [Abstract][Full Text] [Related]  

  • 43. HSP90 expression and early recurrence in gastroenteropancreatic neuroendocrine tumors: Potential for a novel therapeutic target.
    Gamboa AC; Ethun CG; Postlewait LM; Lopez-Aguiar AG; Zhelnin K; Krasinskas A; El-Rayes BF; Russell MC; Kooby DA; Staley CA; Cardona K; Maithel SK
    Surg Oncol; 2020 Dec; 35():460-465. PubMed ID: 33080545
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Localized high-grade gastroenteropancreatic neuroendocrine tumors: Defining prognostic and therapeutic factors for a disease of increasing clinical significance.
    Mosquera C; Koutlas NJ; Fitzgerald TL
    Eur J Surg Oncol; 2016 Oct; 42(10):1471-7. PubMed ID: 27528467
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Incidence Trends of Gastroenteropancreatic Neuroendocrine Tumors in the United States.
    Lee MR; Harris C; Baeg KJ; Aronson A; Wisnivesky JP; Kim MK
    Clin Gastroenterol Hepatol; 2019 Oct; 17(11):2212-2217.e1. PubMed ID: 30580091
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Models of Gastroenteropancreatic Neuroendocrine Neoplasms: Current Status and Future Directions.
    Detjen K; Hammerich L; Özdirik B; Demir M; Wiedenmann B; Tacke F; Jann H; Roderburg C
    Neuroendocrinology; 2021; 111(3):217-236. PubMed ID: 32615560
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Association of the Chronotype Score with Circulating Trimethylamine N-Oxide (TMAO) Concentrations.
    Barrea L; Muscogiuri G; Pugliese G; Graziadio C; Maisto M; Pivari F; Falco A; Tenore GC; Colao A; Savastano S
    Nutrients; 2021 May; 13(5):. PubMed ID: 34069075
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Interpretation and evaluation of the American Joint committee on Cancer (AJCC) 8th Edition Staging System for patients with gastroenteropancreatic neuroendocrine tumors].
    Chen L; Zhou Z; Chen J
    Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Sep; 20(9):972-976. PubMed ID: 28900985
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Surgical treatments for gastroenteropancreatic neuroendocrine tumor (GEP-NET)].
    Aoki T; Kokudo N
    Nihon Shokakibyo Gakkai Zasshi; 2014 Dec; 111(12):2272-9. PubMed ID: 25482902
    [No Abstract]   [Full Text] [Related]  

  • 50. Evaluation of a Correction Method for
    Kanzaki T; Takahashi Y; Higuchi T; Zhang X; Mogi N; Suto T; Tsushima Y
    J Nucl Med Technol; 2020 Dec; 48(4):326-330. PubMed ID: 32887762
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Primary Site Predicts Grade for Gastroenteropancreatic Neuroendocrine Tumors.
    Fitzgerald TL; Mosquera C; Lea CS; McMullen M
    Am Surg; 2017 Jul; 83(7):799-803. PubMed ID: 28738955
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Survival of Patients With Gastroenteropancreatic Neuroendocrine Tumors and Diabetes Mellitus.
    Thapi S; Baeg K; Kim MK; Gallagher EJ
    Pancreas; 2021 Oct; 50(9):1293-1297. PubMed ID: 34860814
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A Consensus-Developed Morphological Re-Evaluation of 196 High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms and Its Clinical Correlations.
    Elvebakken H; Perren A; Scoazec JY; Tang LH; Federspiel B; Klimstra DS; Vestermark LW; Ali AS; Zlobec I; Myklebust TÅ; Hjortland GO; Langer SW; Gronbaek H; Knigge U; Tiensuu Janson E; Sorbye H
    Neuroendocrinology; 2021; 111(9):883-894. PubMed ID: 33002892
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Identification of sequence polymorphisms in the displacement loop region of mitochondrial DNA as a risk factor for gastroenteropancreatic neuroendocrine neoplasm.
    Er LM; Wu ML; Gao Y; Wang SJ; Li Y
    J Clin Lab Anal; 2017 Sep; 31(5):. PubMed ID: 27704598
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor.
    Yoo C; Cho H; Song MJ; Hong SM; Kim KP; Chang HM; Chae H; Kim TW; Hong YS; Ryu MH; Kang YK; Kim SC; Ryoo BY
    Cancer Chemother Pharmacol; 2017 Jan; 79(1):139-146. PubMed ID: 27942928
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Are G3 ENETS neuroendocrine neoplasms heterogeneous?
    Vélayoudom-Céphise FL; Duvillard P; Foucan L; Hadoux J; Chougnet CN; Leboulleux S; Malka D; Guigay J; Goere D; Debaere T; Caramella C; Schlumberger M; Planchard D; Elias D; Ducreux M; Scoazec JY; Baudin E
    Endocr Relat Cancer; 2013 Oct; 20(5):649-57. PubMed ID: 23845449
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evaluating gastroenteropancreatic neuroendocrine tumors through microRNA sequencing.
    Panarelli N; Tyryshkin K; Wong JJM; Majewski A; Yang X; Scognamiglio T; Kim MK; Bogardus K; Tuschl T; Chen YT; Renwick N
    Endocr Relat Cancer; 2019 Jan; 26(1):47-57. PubMed ID: 30021866
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Disseminated Well-Differentiated Gastro-Entero-Pancreatic Tumors Are Associated with Metabolic Syndrome.
    Santos AP; Castro C; Antunes L; Henrique R; Cardoso MH; Monteiro MP
    J Clin Med; 2019 Sep; 8(9):. PubMed ID: 31533348
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Time from first tumor manifestation to diagnosis in patients with GEP-NET: Results from a large German tertiary referral center.
    Koch C; Koca E; Filmann N; Husmann G; Bojunga J
    Medicine (Baltimore); 2021 Sep; 100(37):e27276. PubMed ID: 34664885
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Baseline tumor growth rate highlights the heterogeneity of well differentiated gastroenteropancreatic neuroendocrine tumors and predicts for increases in Ki67 index over time.
    Wang SJ; Whitman J; Paciorek A; Le BK; Nakakura EK; Behr SC; Joseph N; Zhang L; Hope TA; Bergsland EK
    J Neuroendocrinol; 2023 Apr; 35(4):e13260. PubMed ID: 37002881
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.